- Open Access
Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles
© Yuan et al.; licensee BioMed Central. 2015
Received: 6 July 2014
Accepted: 8 January 2015
Published: 27 January 2015
Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that currently lacks effective treatment. Berberine (BBR), a botanic compound isolated from traditional Chinese medicine, exhibits a potent therapeutic potential for the metabolic disease. The current study aimed to understand the mechanisms underlying the therapeutic effect of BBR in NAFLD.
We performed systematical analyses on hepatic expression profiles of mRNAs and long noncoding RNAs (lncRNAs) in a high-fat diet (HFD)-induced steatotic animal model with or without BBR treatment. The study was conducted by using the methods of bioinformatics, including hierarchical clustering, gene enrichment and gene co-expression networks analysis. The effect of BBR on the expression profile of some interesting genes was confirmed by quantitative RT-PCR and further studied in a human hepatic cell line, Huh7.
We found that a large group of genes including 881 mRNAs and 538 lncRNAs whose expression in the steatotic liver was reversed by BBR treatment, suggesting a global effect of BBR in modulating hepatic gene expression profiles. Among the BBR-regulated genes, we identified several modules and numerous significant genes that were associated with liver metabolism and NAFLD-related functions. Specifically, a conserved lncRNA, MRAK052686, was found strongly correlated with the antioxidant factor Nrf2, and both genes were down-regulated by the steatotic liver. Moreover, the reduced expression of MRAK052686 and Nrf2 was completely reversed by BBR treatment, suggesting a new mechanism accounting for the therapeutic effect of BBR.
The findings for the first time provide a new genetic insight into the pharmaceutical mechanism of BBR in protecting against NAFLD.
Nonalcoholic fatty liver disease (NAFLD) has become a worldwide health problem that influences approximately 20–30% of the general population and its prevalence is continuously increasing [1,2]. NAFLD is closely associated with obesity, hyperlipemia and type 2 diabetes, and thus often regarded as atypical hepatic manifestation of the metabolic syndrome . Under certain circumstances, NAFLD can progress from hepatic steatosis to steatohepatitis, leading to an increased susceptibility of cirrhosis and hepatocellular carcinoma . However, there is still a limitation in both mechanistic understanding and clinical management of the disease. Besides life style intervention, several medications, e.g., Metformin, vitamin E and Pioglitazone, are currently applied in the clinic for treatment of NAFLD [4,5]. However, these medications often exhibited a limited efficacy and considerable side effects. Therefore, much effort has been focused on the development of new therapeutics for NAFLD.
Berberine (BBR), isolated from the herb Rhizoma Coptidis, has been widely used in traditional Chinese medicine to treat diarrhea and many other inflammatory diseases . Recent studies have revealed a novel therapeutic role of BBR in metabolic disorders, including obesity and diabetes [7,8]. BBR can function as a cholesterol-lowering drug via a unique mechanism distinct from statins . These findings suggest a potential therapeutic activity of BBR for NAFLD. Indeed, both in vitro and in vivo studies from our previous work and many others have shown that BBR profoundly inhibited lipid synthesis and accumulation in hepatocytes, attenuated hepatic steatosis and hyperlipidemia, and prevented the progression of NAFLD [10-14]. Mechanistically, the therapeutic activity of BBR has been suggested to attribute to its effects of overcoming insulin resistance, reducing endoplasmic reticulum (ER) stress and regulating the signaling pathways, such as the AMPK and JNK pathways [15-18]. More recently, BBR has been shown to modulate gut microbiota, which also account for the therapeutic effect of BBR on the metabolic diseases . It thus appears that multiple mechanisms are involved in the therapeutic effect of BBR, leading us to hypothesize that BBR may have a global effect in modulating gene expression profile in the liver and thereby protecting against hepatic steastosis.
Long noncoding RNAs (lncRNAs) are a novel class of RNA transcripts that are more than 200 bp in length and have little or no protein-coding capacity . According to chromosomal position relative to coding RNAs, lncRNAs are mainly grouped into intergenic, intronic, sense and antisense non-coding RNAs . Most lncRNAs show moderately evolutional conservation and specific transcription . Recently, lncRNAs have been shown widely involved in epigenetic regulation via their direct or indirect interactions with chromatins . Acting as important regulatory molecules, miscellaneous lncRNAs are critically complicated diverse biological processes from normal development and human diseases [24,25]. However, there are little studies on lncRNA in NAFLD. In an attempt to further understand the mechanisms underlying the therapeutic effect of BBR, we performed systematical analyses on hepatic expression profiles of mRNAs and lncRNAs in a high-fat diet (HFD)-induced steatotic animal model with or without BBR treatment as reported in the present study.
Materials and methods
Animal studies were approved by the Animal Use and Care Committee of Fudan University and were in conformity with the US Public Health Service Policy on Humane Care and Use of Laboratory Animals. Total 24 healthy male Sprague-Dawley rats weighing around 200 g were obtained from the Animal Development Center, Chinese Academy of Sciences, Shanghai. All rats were acclimated for 1 week before initiation of the experiment and maintained on a 12/12 h light/dark cycle with free access to food and water. The animals were divided to the following three groups (8 rats per group): (i) Control group (ND group), received a regular rodent chow diet (62.3% carbohydrate, 12.5% fat and 24.3% protein in total calories); (ii)HFD group, fed a HFD (32.6% carbohydrate, 51.0% fat and 16.4% protein) for 24 weeks; and (iii) HFD + BBR group, after 8 weeks of HFD feeding, rats were orally treated with BBR (Sigma, St. Louis, USA) at a dose of 200 mg/kg/day via a lavage needle and fed on HFD feeding for 16 weeks. Animals received intraperitoneal glucose tolerance tests (IPGTT), weekly measurements of body weight and food intake, and monthly tests of fasting serum insulin and glucose as described previously . Hepatic lipids were extracted according to the method of Folch et al.  and triglyceride content was tested as described previously . Fasting serum levels of total cholesterol and low-density lipoprotein cholesterol (LDL-c) were measured using an Amplex Red Cholesterol Assay Kit (A12216, Molecular Probes Invitrogen Detection Technologies) according to the manufacturer’s protocol.
All liver samples were collected after animals were sacrificed in 24th week of the treatment and subsequently fixed in phosphate-buffered 10% formalin. The right lateral lobule of each liver was embedded in paraffin blocks and stained with hematoxylin and eosin (H&E) examining the pathologic features of the liver.
Microarrays of mRNAs and lncRNAs
Arraystar Rat LncRNA microarrays (accession in NCBI Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo: GPL15690) were used for measuring the expression profiles of lncRNAs and mRNAs in total 15 rats (i.e., 3 groups at 5 replicates). The sample preparations and microarray hybridization were performed based on the manufacturer’s protocols. Briefly, 1 μg of total RNA from each sample was amplified and transcribed into fluorescent cRNA using Agilent’s Quick Amp Labeling kits according to the manufacturer’s protocol (version 5.7, Agilent Technologies). The labeled cRNAs were hybridized onto the Rat LncRNA Arrays (4×44K, Arraystar, Rockville, USA). After washing, the arrays were scanned by the Agilent Scanner G2505B. Raw signal intensities were normalized in quantile method by GeneSpring GX v11.5.1. After filtration of low intensity RNAs, those RNAs with flags in Present or Marginal at least 1 out of 15 samples were chosen for further analysis. Differentially expressed genes were identified by using the Limma package . The threshold set for significantly differential genes was an absolute log value of fold change ≥ 0.6 and a p value < 0.05.
Hierarchical clustering and gene enrichment analysis
We took Euclidean distance with a complete linkage to hierarchically cluster the genes across the samples. Unsupervised hierarchical clustering and the visualization of heatmap were performed using the R platform (http://www.r-project.org/). Gene function enrichment analysis was performed by using DAVID . The significance of enrichment was calculated by hypergeometric test and adjusted by Benjamini method. GO (gene ontology) and KEGG (kyoto encyclopedia of genes and genomes) were accessed from the databases of http://www.geneontology.org/ and http://www.genome.jp/, respectively [30,31].
Gene module-trait relationships
We analyzed associations between gene modules and the traits by using WGCNA (weighted correlation network analysis) package . The package assessed module-trait relationships by correlating of each module eigengene (the first principal component of gene expression in the module) with the traits.
Construction of gene co-expression networks
We constructed and analyzed the co-expression network of lncRNAs and mRNAs using WGCNA package. The weight of edges was scaled by a soft power of correlation coefficient of parewise genes, and the soft power was set to 16 after stimulation. The visualization and layout of network were achieved by cytoscape software .
Prediction for protein-coding potential and interaction propensity of lncRNAs
The protein-coding potential of lncRNAs was predicted by PhyloCSF which calculates codon substitution frequencies (CSF) determining whether a multispecies nucleotide sequence is conserved protein-coding region . The more positive value of CSF indicates a higher potential to code protein, vice versa. Multiple alignments of 8 vertebrate genomes are downloaded from UCSC (http://genome.ucsc.edu/). We used catRAPID to predict the interaction propensity of lncRNAs with proteins . The software catRAPID computes interaction propensity (IP, a measure based on physico-chemical profiles of ribonucleoprotein complexes) and discriminative power (DP) for assessing the potential of interaction. DP above 75% represents highly confident IP.
Identification of human homologous of the lncRNA MRAK052686
According to genome-wide alignment from UCSC (http://genome.ucsc.edu) and chromosomal position, we found that human MRAK052686 is located around ZBTB20. A direct searching of MRAK052686 in human genome indicated the same chromosomal location as mentioned above. By searching this human locus in ENSMBL database (http://www.ensembl.org) and then aligning sequences, we found 6 of 11 non-coding transcripts with a high similarity to rat MRAK052686 (Additional file 1: Table S1 and Additional file 2: Figure S1). These six lncRNAs were thus regarded as human homologues of MRAK052686.
Cell culture, treatment and intracellular lipid staining
Huh7, a human hepatoma cell line, was obtained from American Type Culture Collection (Manassas, VA) and routinely cultured in DMEM supplemented with 10% fetal bovine serum. For treatment, a stock solution of 100 mM oleic acid with 11% (w/v) fatty acid-free BSA was prepared. When reaching a 70% confluence, cells were washed with PBS and exposed to 100 μM OA for 24 h in the presence or absence of 10 μM BBR. For intracellular lipid staining, cells were washed with PBS three times and fixed with 4% paraformaldehide for 30 min. Intracellular lipids were stained with Nile Red (Sigma, St. Louis, USA) for 15 min and nuclei stained with DAPI for an additional 5 min. Images were photographed with an inverted fluorescence microscope (Leica DM2000, Wetzlar, Germany).
Real-time quantitative PCR
All rats were euthanized and their livers were collected after 24 weeks treatment. Total RNA was isolated from liver tissues using Trizol reagent (Invitrogen, Carlsbad, CA). cDNA was synthesized by reverse transcription in a 20 μL reaction system using PrimeScript kit (Takara, Tokyo, Japan). The reverse transcription reactions were conducted at 37°C for 15 min and inactivated at 85°C for 30s using an automatic thermocycler according to manufacturer’s instruction. Real-time quantitative PCR (RT-qPCR) was performed with an Applied Biosystems 7500 using SYBR Premix EX Taq (Takara, Tokyo, Japan). A total 10 μL reaction mixture contained of 5 ng sample cDNA, 5 μM specific forward and reverse primers, and 5 μL SYBR Premix EX Taq. The sequences of primers used for RT-qPCR are shown in Additional file 1: Table S2. The PCR reaction was consisted of an initial denaturation cycle at 95°C for 10 min and 40 amplification cycles of 95°C for 15 s and 60°C for 1 min. The relative gene expression was calculated using the 2-ΔΔCt method . The same reaction was carried out in triplicate with β-actin as an internal control. Experiments of each condition were conducted in 3 replicates.
All data were presented as mean ± SEM. Significance was assessed by one-way ANOVA followed by Tukey’s test and LSD for multiple comparisons. Chi-square test was used to assess the significance of variables in the contingency table. All statistics were performed in R platform. A value of p < 0.05 was considered statistically significant.
BBR ameliorates hepatic steatosis in HFD-fed rats
BBR systematically modulates hepatic gene expression
Expression profiles of BBR-regulated genes
In order to further characterize the effect of BBR on hepatic gene regulation, we specifically grouped the genes whose expression was potentially regulated by BBR. To this end, we used the following criteria to determine the genes as BBR-regulated genes: (i) the gene expression was inversely changed in two comparisons, and (ii) absolute log value of fold change ≥ 0.6 in the first comparison between HFD + BBR and HFD groups. Accordingly, total 881 mRNAs and 538 lncRNAs were identified as BBR-regulated genes whose expression patterns were reversed after BBR treatment in comparison to HFD group (Figure 2A, Additional file 4: Table S3).
Based on the above seven BBR-regulated modules, we assessed the correlation of NAFLD-related traits with the module eigengenes using WGCNA package . We found that salmon module was mostly correlated with triglyceride metabolism and red module associated with lipoproteins (Additional file 6: Figure S4). Of note, function enrichment analysis by using DAVID  indicated that the salmon and red modules are likely associated with NAFLD, including the genes involved in endoplasmic reticulum (ER) function and fatty acid metabolism (Figure 3B, and Additional file 1: Table S4). In addition, mRNAs in dark golden module is also related to NAFLD, including the genes involved in fat-soluble vitamin metabolic process. Collectively, these data indicate that a large number of BBR-regulated genes including lncRNAs are indeed functionally associated with NAFLD (especially those from salmon, red and dark golden modules).
The lncRNA MRAK052686 is a significant BBR-regulated gene
MRAK052686 is located in 3’UTR of protein-coding gene Zbtb20, which is an important regulator of glucose homeostasis and has been reported to associate with liver dysfunction . However, we found no difference in Zbtb20 expression between HFD + BBR and HFD groups (data not shown) and no correlation of Zbtb20 to MRAK052686. This suggests that MRAK052686 is a transcript independent of Zbtb20. Further analysis indicated that codon substitution frequency of MRAK052686 is strongly negative (Additional file 9: Figure S7). Moreover, we found no protein sequence significantly matched with MRAK052686 from NCBI reference protein database (data not shown), further suggesting that MRAK052686 has no or little potential to code protein.
BBR restores the decreased expression of MRAK052686 and Nrf2 in steatotic liver
Multiple lines of evidences from both in vivo and in vitro studies have demonstrated a therapeutic potential of the botanic compound BBR in metabolic diseases, including obesity and diabetes [7,8,10-14]. In the present, we were able to confirm the effect of BBR in amelioration of NAFLD in HFD-induced obese rats as reported previously [12,14]. By analyzing gene expression profiles, we identified 5, 271 mRNAs and 3, 265 lncRNAs, which displayed differential expression patterns among the control, HFD and HFD + BBR treated animals. We further refined a large group of BBR-regulated genes, including 881 mRNAs and 538 lncRNAs whose expression was reversed between HFD and HFD + BBR groups, demonstrating a potent effect of BBR in globally altering hepatic gene expression. Moreover, by modularization of the BBR-regulated genes, we delineated several modules and identified numerous significant genes exhibiting a wide association with liver metabolism and NAFLD-related functions. The findings thus, for the first time, provide a genetic basis for understanding the pharmaceutical mechanism of BBR in protection against multiple metabolic diseases, including NAFLD.
Of interesting, not only were over 800 of BBR-regulated mRNAs identified in the current study, but also more than 500 aberrant lncRNAs in NAFLD were reversed by BBR treatment (Figure 2A). The number of altered lncRNAs was comparable with that of mRNAs. Although the precise roles of these lncRNAs in NAFLD are currently unknown, lncRNAs have emerged as important regulators of gene expression related to metabolic homeostasis or dysfunction. For instance, it was reported that near two hundreds of lncRNAs were regulated during the process of adipogenesis and many of them were bound at their promoters by key transcription factors such as PPARγ and CEBPα . Furthermore, RNAi-mediated loss of function screens identified numerous lncRNAs that were required for proper adipogenesis . There is a large body of evidences that lncRNAs can regulate gene expression both in cis and in trans by forming RNA-protein, DNA-RNA, protein-DNA and RNA-RNA interactions . In the current study, we found that a total of 538 lncRNAs were regulated in the liver by BBR treatment in HFD-induced obese rats. Among these BBR-regulated lncRNAs, a set of lncRNAs was significantly associated with triglyceride trait (Additional file 8: Figure S6). In the analysis of co-expression sub-networks, we identified numerous lncRNAs were located in the salmon and dark golden modules, which are functionally linked with NAFLD-related genes (Figure 4 and Additional file 8: Figure S6). A significant example of these lncRNAs is MRAK052686. We found that MRAK052686 expression associated with Eif2ak2 and Nrf2 (Figure 4), the two genes that are critically involved in NAFLD. By bioinformatics prediction, we found the interaction propensity and discriminative power of Nrf2 and Eif2ak2 interacting with MRAK052686 are far stronger than that of the control genes Actb and Gapdh (Additional file 10: Figure S8). Indeed, a strong co-expression of MRAK052686 and Nrf2 was demonstrated by either microarray analysis or the experimental data from HFD-fed animals (Figure 5). This implies a potential role of MRAK052686 in regulation of Nrf2 expression.
Nrf2 is a master transcription factor that regulates expression of many genes that are involved in antioxidant, metabolism and ER stress response [38,42]. In mammalian, Nrf2 is regarded as a major cellular sensor of oxidative stress, which constitutes downstream the PERK (PKR-like ER-kinase) pathway during ER stress response . Upon PERK activation, Nrf2 is activated and binds to the antioxidant response elements in the regulatory regions of target genes, thereby regulating ER stress response [43,44]. Besides, Eif2ak2, another associated gene with MRAK052686, is actually a homologue of PERK. Moreover, Gcs1 that was also co-expressed with MRAK052686 functions in ER protein processing and regulates ER stress response. Indeed, ER stress has been well documented as a pivotal pathogenic event contributing to the process of hepatic steatosis [45,46]. The findings that MRAK052686 associates with several key molecules of the ER stress response pathways suggest that MRAK052686 may play important roles in NAFLD by affecting ER stress response, which warrants further investigations.
In the present study, another key finding is that most of the aberrantly expressed genes, including numerous lncRNAs, in HFD-induced hepatic steatosis were reversed by BBR treatment. In modularization of the sub-networks from salmon and dark golden modules, much more lncRNAs were co-expressed with enriched NAFLD-related mRNAs. This not only demonstrates a global effect of BBR on the alteration of gene profiles, but also suggests a population of lncRNAs as a whole target of the therapeutic action of BBR. Correspondingly, BBR exerts its effect to alleviate NAFLD through a systematic modulation of gene expression including lncRNAs in the liver, providing a potential novel therapeutic agent for the treatment of NAFLD.
By analyzing hepatic gene expression profiles, we found that HFD-induced steatosis in rats resulted in a globe alteration in hepatic gene expression, which was significantly reversed by BBR treatment. Several modules of BBR-regulated genes, including abundant lncRNAs, were identified by bioinformatics analysis. Among these BBR-regulated genes, we found that the lncRNA MRAK052686 and its associated gene Nrf2 appear implicating in the pathogenesis of NAFLD. Thus, the study provides a new genetic insight into the pharmaceutical mechanism of BBR in protecting against NAFLD.
This work was supported by grants from the Major State Basic Research Development Program of China (2012CB524906 to X.G.; http://www.973.gov.cn/Default_3.aspx), National Natural Science Foundation of China (81270933 to X.G. and 81370937 to P.X.).
- Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899–905.PubMed CentralPubMedView ArticleGoogle Scholar
- Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–23.PubMed CentralPubMedView ArticleGoogle Scholar
- Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84–129.PubMedView ArticleGoogle Scholar
- Armstrong MJ, Houlihan DD, Rowe IA. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;363:1185–6.PubMedView ArticleGoogle Scholar
- Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–68.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhang J, Cao H, Zhang B, Cao H, Xu X, Ruan H, et al. Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling. J Cell Mol Med. 2013;17:1484–93.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59:285–92.PubMedView ArticleGoogle Scholar
- Zhou L, Wang X, Yang Y, Wu L, Li F, Zhang R, et al. Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes. Biochim Biophys Acta. 2011;1812:527–35.PubMedView ArticleGoogle Scholar
- Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344–51.PubMedView ArticleGoogle Scholar
- Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res. 2006;47:1281–8.PubMedView ArticleGoogle Scholar
- Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009;296:E812–9.PubMedView ArticleGoogle Scholar
- Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D, et al. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res. 2010;51:2504–15.PubMed CentralPubMedView ArticleGoogle Scholar
- Ge Y, Zhang Y, Li R, Chen W, Li Y, Chen G. Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes. Int J Biol Sci. 2011;7:673–84.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhao HL, Sui Y, Qiao CF, Yip KY, Leung RK, Tsui SK, et al. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes. 2012;61:933–43.PubMed CentralPubMedView ArticleGoogle Scholar
- Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, et al. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta. 2006;1760:1682–9.PubMedView ArticleGoogle Scholar
- Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256–64.PubMedView ArticleGoogle Scholar
- Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57:1414–8.PubMedView ArticleGoogle Scholar
- Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900–17.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7:e42529.PubMed CentralPubMedView ArticleGoogle Scholar
- Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23:1494–504.PubMed CentralPubMedView ArticleGoogle Scholar
- Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.PubMedView ArticleGoogle Scholar
- Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–41.PubMedView ArticleGoogle Scholar
- Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–14.PubMed CentralPubMedView ArticleGoogle Scholar
- Pauli A, Rinn JL, Schier AF. Non-coding RNAs as regulators of embryogenesis. Nat Rev Genet. 2011;12:136–49.PubMed CentralPubMedView ArticleGoogle Scholar
- Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354–61.PubMedView ArticleGoogle Scholar
- Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497–509.PubMedGoogle Scholar
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.PubMedView ArticleGoogle Scholar
- Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067–75.PubMedView ArticleGoogle Scholar
- Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.View ArticleGoogle Scholar
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. the gene ontology consortium. Nat Genet. 2000;25:25–9.PubMed CentralPubMedView ArticleGoogle Scholar
- Altermann E, Klaenhammer TR. Pathway voyager: pathway mapping using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. BMC Genomics. 2005;6:60.PubMed CentralPubMedView ArticleGoogle Scholar
- Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.PubMed CentralPubMedView ArticleGoogle Scholar
- Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, et al. A travel guide to Cytoscape plugins. Nat Methods. 2012;9:1069–76.PubMed CentralPubMedView ArticleGoogle Scholar
- Lin MF, Jungreis I, Kellis M. PhyloCSF: a comparative genomics method to distinguish protein coding and non-coding regions. Bioinformatics. 2011;27:i275–82.PubMed CentralPubMedView ArticleGoogle Scholar
- Agostini F, Zanzoni A, Klus P, Marchese D, Cirillo D, Tartaglia GG. catRAPID omics: a web server for large-scale prediction of protein-RNA interactions. Bioinformatics. 2013;29:2928–30.PubMed CentralPubMedView ArticleGoogle Scholar
- Xing LJ, Zhang L, Liu T, Hua YQ, Zheng PY, Ji G. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol. 2011;668:467–71.PubMedView ArticleGoogle Scholar
- Teodoro JS, Duarte FV, Gomes AP, Varela AT, Peixoto FM, Rolo AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation. Mitochondrion. 2013;13:637–46.PubMedView ArticleGoogle Scholar
- Cullinan SB, Diehl JA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem. 2004;279:20108–17.PubMedView ArticleGoogle Scholar
- Sutherland AP, Zhang H, Zhang Y, Michaud M, Xie Z, Patti ME, et al. Zinc finger protein Zbtb20 is essential for postnatal survival and glucose homeostasis. Mol Cell Biol. 2009;29:2804–15.PubMed CentralPubMedView ArticleGoogle Scholar
- Sun L, Goff LA, Trapnell C, Alexander R, Lo KA, Hacisuleyman E, et al. Long noncoding RNAs regulate adipogenesis. Proc Natl Acad Sci U S A. 2013;110:3387–92.PubMed CentralPubMedView ArticleGoogle Scholar
- Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482:339–46.PubMed CentralPubMedView ArticleGoogle Scholar
- DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106–9.PubMed CentralPubMedView ArticleGoogle Scholar
- Xu J, Kulkarni SR, Donepudi AC, More VR, Slitt AL. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes. 2012;61:3208–18.PubMed CentralPubMedView ArticleGoogle Scholar
- Okada K, Warabi E, Sugimoto H, Horie M, Gotoh N, Tokushige K, et al. Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. J Gastroenterol. 2013;48:620–32.PubMedView ArticleGoogle Scholar
- Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology. 2006;147:943–51.PubMedView ArticleGoogle Scholar
- Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134:568–76.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.